Product Images Eliquis
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Eliquis NDC 70518-1861 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Eliquis 5mg 70518 1861 01
Eliquis (Apixaban) is a prescription-only medication manufactured by BristolMyers Squibb and Pfizer, Princeton, NJ Te5as. It has an NDC# of 70518-1861-01 and expiration date and LOT# are not available. The medication should be stored in a cool, dry place and kept out of reach of children. RemedyRepack Inc. located in Indiana, PA 15701 has repackaged this medication. For usage directions, kindly refer to the package insert.*
Eliquis 5mg 70518 1861 02
Eliquis, also known as Apixaban, is a medication that requires a prescription. It comes in a 70518-1861-02 NDC package with an expiry date and LOT number. BristolMyers Squibb and Pfizer manufacture it in Princeton, NJ and Texas. To keep children safe, the medication should be stored at 20-26°C (63-77°F) within acceptable excursions of 15-30°C (59-86°F) [See USP]. Directions for use can be found in the package insert. This drug is repackaged by RemedyRepack Inc. in Indiana, PA 15701.*
Remedy_Label - Remedy Label
Eliquis (Apixaban) is a prescription-only medication manufactured by Bristol Myers Squibb and Pfizer. The medicine comes with an NDC # of 70518-1861-00 and the source NDC is 00003-0894-21. The lot number and expiration date are not available. The package insert should be consulted for proper usage. It should be stored between 20-26°C (63-77°F); excursions permittedto 15-30°C (59-86°F). The medication should be kept away from children. This particular package was repackaged by RemedyRepack Inc. in Indiana.*
Apixaban Chemical Structure - apixaban struct
ARISTOTLE Forest Plot - eliquis clin forest fig5
ARISTOTLE Major Bleeding Forest Plot - eliquis forest fig1
ARISTOTLE Kaplan-Meier Curve - eliquis km fig4
Not-Available.*
Effect of Coadministered Drugs on Pharmacokinetics of Apixaban - eliquis pkplot drugs fig2
This appears to be a pharmacokinetic analysis of the fold change and 90% confidence interval of drugs that interact with P-gp and Strong CYP3A4 inhibitors or strong CYP3A4 inducer. The text lists specific drugs and their respective doses, as well as the AUC (area under the curve) values for certain compounds. The chart at the bottom shows relative changes in drug PK (pharmacokinetics) compared to a reference value.*
O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08. PAS ESRD Dosing\01. Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg - eliquis pkplot pop fig3
The text appears to be a table or chart that provides information on population description, PK fold change, 90% CI, and dosing recommendations for different conditions such as renal impairment, age, and body weight. It seems to suggest that for some conditions, dose adjustment is not needed, while for others, a dosing recommendation cannot be provided. Without more context or clarity, it is difficult to provide a more detailed description of the information presented.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.